NCT04079231View on ClinicalTrials.gov

Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 1, 2021

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Diabetic Macula Edema
Interventions
DRUG

Brolucizumab

Intravitreal Injection

DRUG

Aflibercept

Intravitreal injection

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY